(Q36788450)

16 August 2017

1 reference

title

Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

Philip Bonomi

1

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

415-422

1 reference

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Estrogen receptor regulation of pulmonary alveolar dimensions: alveolar sexual dimorphism in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Hormone replacement therapy is associated with decreased survival in women with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Second-line treatment for advanced non-small cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Relationships between the structure of taxol analogs and their antimitotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Microvascular permeability of normal and neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.415

21 January 2018

Identifiers

DOI

10.1586/14737140.7.4.415

1 reference

16 August 2017

1 reference